FDA Approves Nivolumab for Head and Neck Cancer

The FDA has approved nivolumab for squamous cell carcinoma of the head and neck that has progressed during chemotherapy with a platinum-based drug or that has recurred or metastasized after platinum-based chemotherapy.

Cancer Currents: An NCI Cancer Research Blog